Compare Cassava Sciences Inc (FLNA) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Las Vegas Sands Corp. — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Las Vegas Sands Corp. trades at $45.76 (market cap $29.68B). The key difference: Las Vegas Sands Corp. is far larger — about 558.5× Cassava Sciences Inc's market cap, and Las Vegas Sands Corp. pays a 2.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LVS | |
|---|---|---|
Market Cap | $53.14M | $29.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $69.49 |
52-Week Low | $1.09 | $44.78 |
Enterprise Value | -$33.43M | $42.07B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
LVS trades at $45.40, up 1.38% with strong earnings beats in recent quarters. Technical indicators show bearish momentum despite oversold RSI levels near support at $44. Fundamentally, revenue grew to $13.02B in 2025 with net income of $1.63B, though debt levels remain elevated at 73.15% of assets. Recent news highlights ESG achievements and Macao expansion efforts.
Analyst consensus is bullish with a $65.40 price target (61% buy ratings), but high leverage and bearish technical signals pose near-term risks. Upside depends on sustained gaming recovery and debt management, while macroeconomic pressures could challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
